<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03240328</url>
  </required_header>
  <id_info>
    <org_study_id>20170407V3</org_study_id>
    <nct_id>NCT03240328</nct_id>
  </id_info>
  <brief_title>The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function</brief_title>
  <official_title>The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou 8th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and effectiveness of CAR-T Cell Therapy on HIV patients whose plasma HIV
      has been successfully suppressed after cART, which is expected to enhance the
      res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the advent of combined antiretroviral therapy (cART), the persistence of viral
      reservoirs remains a major barrier to curing human immunodeficiency virus type 1 (HIV-1)
      infection. Recently, the shock and kill strategy, by which such reservoirs are eradicated
      following reactivation of latent HIV-1 by latency-reversing agents (LRAs), has been
      extensively practiced. It is important to reestablish virus-specific and reliable immune
      surveillance to eradicate the reactivated virus-harboring cells.the VC-CAR-T cells
      effectively induced the cytolysis of LRA-reactivated HIV-1-infected CD4 T lymphocytes
      isolated from infected individuals receiving suppressive cART. Our previous study
      demonstrated that the special features of genetically engineered CAR-T cells make them a
      particularly suitable candidate for therapeutic application in efforts to reach a functional
      HIV cure.In this clinical trial, we intend to study the safety and effectiveness of CAR-T
      Cell Therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, by
      observing the adverse events and the immunity(CD4,Th1/Th2 and VC-CAR-T) and HIV viral load of
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The control arm includes HIV-infected patients without receiving celluar therapy whose HIV has been successfully suppressed after cART.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events of CAR-T cell therapy</measure>
    <time_frame>6 Months</time_frame>
    <description>The adverse events of VC-CAR-T cell therapy on HIV-infected patients during the clinical trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The HIV reservoir</measure>
    <time_frame>6 Months</time_frame>
    <description>To assay the HIV loads in the peripheral blood Mono-nuclear cells and plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The HIV-specific immunity</measure>
    <time_frame>6 Months</time_frame>
    <description>The number of HIV-specific CD4,CD8 and VC-CAR-T cells in patients with HIV after receiving CAR-T cell therapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>CAR-T therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfuse CAR-T cells 1 million clone every time (totally twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA &lt;50 cp/ml) over 1 year by cART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without CAR-T therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without CAR-T cells transfusion but continue cART after attaining plasma HIV suppression (plasma HIV RNA &lt;50 cp/ml) over 1 year by cART.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cells</intervention_name>
    <description>HIV-1 specific chimeric antigen receptor cells</description>
    <arm_group_label>CAR-T therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV infection confirmed

          2. Receiving HAART more than 6 months

          3. HIV viral-load &lt; 50 copies/ml

          4. Without serious damage of liver and kidney

          5. The subject volunteered to the research and sign the informed consent

        Exclusion Criteria:

          1. With serious opportunistic infections

          2. With serious chronic disease such like diabetes, the mental illness,et al

          3. History of suffering from pancreatitis during HAART.

          4. Pregnant and breast-fed. With poor adherence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cai Weiping, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou 8th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Linghua, Doctor</last_name>
    <phone>13725297174</phone>
    <email>llheliza@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cai Weiping, Bachelor</last_name>
    <phone>13808815909</phone>
    <email>gz8hcwp@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou 8th People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linghua LI, doctor</last_name>
      <phone>13725297174</phone>
      <email>llheliza@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.</citation>
    <PMID>23527958</PMID>
  </reference>
  <reference>
    <citation>Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.</citation>
    <PMID>22160384</PMID>
  </reference>
  <reference>
    <citation>Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.</citation>
    <PMID>25319501</PMID>
  </reference>
  <reference>
    <citation>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2016 Mar 10;374(10):998. doi: 10.1056/NEJMx160005.</citation>
    <PMID>26962747</PMID>
  </reference>
  <reference>
    <citation>Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. N Engl J Med. 2011 Nov 17;365(20):1937-8; author reply 1938. doi: 10.1056/NEJMc1111004.</citation>
    <PMID>22087695</PMID>
  </reference>
  <reference>
    <citation>Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991 Mar 8;64(5):1037-46.</citation>
    <PMID>1900456</PMID>
  </reference>
  <reference>
    <citation>Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology. 2013 Nov;446(1-2):268-75. doi: 10.1016/j.virol.2013.08.002. Epub 2013 Sep 6.</citation>
    <PMID>24074590</PMID>
  </reference>
  <reference>
    <citation>Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric receptor CD4Î¶ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells. 2014 Apr;32(4):1021-31. doi: 10.1002/stem.1611.</citation>
    <PMID>24307574</PMID>
  </reference>
  <reference>
    <citation>MacLean AG, Walker E, Sahu GK, Skowron G, Marx P, von Laer D, Junghans RP, Braun SE. A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol. 2014 Oct;43(5):341-8. doi: 10.1111/jmp.12137. Epub 2014 Aug 20.</citation>
    <PMID>25138734</PMID>
  </reference>
  <reference>
    <citation>Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG. HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Mol Ther. 2015 Aug;23(8):1358-1367. doi: 10.1038/mt.2015.102. Epub 2015 Jun 8.</citation>
    <PMID>26050990</PMID>
  </reference>
  <reference>
    <citation>Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. J Virol. 2015 Jul;89(13):6685-94. doi: 10.1128/JVI.00474-15. Epub 2015 Apr 15.</citation>
    <PMID>25878112</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>April 22, 2018</last_update_submitted>
  <last_update_submitted_qc>April 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou 8th People's Hospital</investigator_affiliation>
    <investigator_full_name>Linghua LI</investigator_full_name>
    <investigator_title>Vice Chief physician</investigator_title>
  </responsible_party>
  <keyword>CAR-T HIV therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

